# Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

> **NCT03898583** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 15 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Microarray patch A
- **DRUG:** Microarray patch B
- **DRUG:** Placebo
- **DRUG:** Daivobet

## Key facts

- **NCT ID:** NCT03898583
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-15
- **Primary completion:** 2019-10-29
- **Final completion:** 2019-10-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03898583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03898583, "Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03898583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*